Naslov
Patient with psoriasis, psoriatic arthritis and hidradenitis suppurativa treated with secukinumab: a case report

Autori
Čarija, Antoanela ; Bubić, Ana ; Puizina Ivić, Neira

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni

Izvornik
JEADV. Journal of the European Academy of Dermatology and Venerology / - , 2019, 85-85

Skup
6th Congress of the Skin Inflammation and Psoriasis International Network

Mjesto i datum
Pariz, Francuska, 25.04.2019. - 27.04.2019

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
Hidradenitis suppurativa, Psoraisis, Psoriatic arthritis, Secukinumab

Sažetak
Background: Secukinumab is a human IgG1κ monoclonal antibody that inhibits interleukin (IL) 17A which is upregulated in serum of people with psoriasis and in the synovial fluid of people with psoriatic arthritis. IL -17A promotes inflammation when it binds to the IL-17 receptor which is expressed in keratinocytes Objectives: In this report we present a case of mid-age woman with psoriasis, psoriatic arthritis, hidradenitis suppurativa and multiple comorbidities treated with secukinumab. Methods: A 50-year old-woman presented with psoriasis, psoriatic arthritis and hidradenitis suppurativa also suffered liver cirrhosis, oesophageal varices, diabetes mellitus, depression and demyelinating lesions on the brain. She had psoriasis for 27 years and was treated by using corticosteroids locally, phototherapy and coal tar products but without improvement and was referred to our department with Psoriasis Area Severity Index (PASI) score 28.6. Methotrexate was contraindicated because of liver cirrhosis. Laboratory finding verified a normal values of hepatitis B and C markers and HIV and tests of occult bleeding were negative. Quantiferon test was positive and latent Mycobacterium tuberculosis infection was confirmed. The patient was treated with Isoniazid 300 mg daily during 6 months and by the present chronic therapy. Results: After that we started treatment with secukinumab monotherapy which was well tolerated and with no side effect. TNFa inhibitors were excluded because of demyelinating lesions on the brain and latent Mycobacterium tuberculosis infection. Our observation suggests that secukinumab could be a safe therapeutic option in patients with moderate to severe psoriasis and multiple comorbidities in which the majority of conventional systemic agents are contraindicated.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA